Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2191 to 2205 of 8915 results

  1. Zanubrutinib for Chronic lymphocytic leukaemia (CLL) or Follicular lymphoma or Marginal zone lymphoma (MZL) or Waldenstrom's macroglobulinaemia [ID12199]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Lomitapide for treating homozygous familial hypercholesterolaemia in people 5 to 17 years [TSID 12085]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Eptinezumab for preventing cluster headache attacks TSID 12087

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years [TSID12092]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Avatrombopag for treating primary chronic immune thrombocytopenia in people 1 to 17 years [TSID12109]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Linaclotide acetate for treating functional constipation in people 6 to 17 years [TSID12125]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Clindamycin for treating bacterial vaginosis in females aged 12 and older [TSID 12127]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Lebrikizumab for treating atopic dermatitis in children [TSID12133]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Vedolizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years [TSID12134]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Lebrikizumab for treating atopic dermatitis in children [TSID 12133_TSID 12135]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Ocrelizumab for treating relapsing–remitting multiple sclerosis in people 10 to 17 years [TSID12164]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation